Zhejiang Risun Intelligent Technology Co.,Ltd (SHA:688215)

Verve Therapeutics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	53.72	67.31	66.96	94.93	60.11	243.64
Short-Term Investments	10.87	10.79	-	12.87	60	-
Cash & Short-Term Investments	64.59	78.09	66.96	107.8	120.11	243.64
Cash Growth	-8.71%	16.63%	-37.89%	-10.25%	-50.70%	774.23%
Accounts Receivable	265.65	276.63	227.2	206.32	142.09	117.49
Other Receivables	4.5	4.2	2.91	-	0.54	1.03
Receivables	270.15	280.83	230.11	206.32	142.63	118.52
Inventory	217.18	171.12	154.36	133.82	78.02	29.86
Other Current Assets	20.31	20.5	15.03	11.7	17.86	11.83
Total Current Assets	572.22	550.54	466.46	459.65	358.62	403.84
Property, Plant & Equipment	212.91	212.31	223.31	220.14	122.42	56.95
Long-Term Investments	13.15	13.07	21.21	10.14	90	40
Other Intangible Assets	20.64	21.02	21.27	18.88	19.02	19.13
Long-Term Accounts Receivable	-	-	-	-	-	0.67
Long-Term Deferred Tax Assets	11.05	10.25	10.33	9.29	5.34	3.71
Long-Term Deferred Charges	0.35	0.4	0.42	0.38	0.29	0.08
Other Long-Term Assets	-	-	-	0.16	3.46	-
Total Assets	830.32	807.58	743	718.63	599.15	524.39
Accounts Payable	69.36	74.08	54.29	48.05	55	46.67
Accrued Expenses	8.07	16.64	22.1	20.99	12.74	5.9
Short-Term Debt	121.55	101.03	78.82	51.84	41.24	13.02
Current Portion of Long-Term Debt	-	0.2	-	-	-	-
Current Portion of Leases	2.56	2.03	2.22	1.61	1.32	-
Current Income Taxes Payable	2.66	2.17	3.1	0.96	0.23	-
Current Unearned Revenue	91.91	77.72	78.83	79.58	39.4	21.79
Other Current Liabilities	14.71	20.9	16.48	44.76	3.98	1.36
Total Current Liabilities	310.83	294.77	255.83	247.78	153.91	88.74
Long-Term Debt	14.38	13.88	-	-	-	-
Long-Term Leases	3.1	0.2	1.82	2.61	0.97	-
Long-Term Unearned Revenue	1.46	1.52	1.74	-	-	-
Long-Term Deferred Tax Liabilities	0.85	0.38	0.64	1.05	0	-
Other Long-Term Liabilities	-	-	-	-	1.35	1.35
Total Liabilities	330.62	310.75	260.03	251.44	156.24	90.09
Common Stock	52.05	52.05	40.04	40.04	40.04	40.04
Additional Paid-In Capital	284.83	284.83	296.84	291.67	291.67	291.67
Retained Earnings	130.15	128.16	116.16	109.69	106.1	98.85
Treasury Stock	-1.3	-0.98	-	-	-	-
Total Common Equity	465.74	464.06	453.04	441.39	437.81	430.56
Minority Interest	33.96	32.77	29.93	25.8	5.11	3.75
Shareholders' Equity	499.69	496.83	482.97	467.19	442.92	434.3
Total Liabilities & Equity	830.32	807.58	743	718.63	599.15	524.39
Total Debt	141.6	117.33	82.86	56.06	43.54	13.02
Net Cash (Debt)	-77.01	-39.24	-15.91	51.75	76.58	230.62
Net Cash Growth	-	-	-	-32.42%	-66.80%	1453.93%
Net Cash Per Share	-1.25	-0.63	-0.26	0.83	1.22	4.44
Filing Date Shares Outstanding	62.5	62.26	62.5	62.5	62.5	62.5
Total Common Shares Outstanding	62.5	62.26	62.5	62.5	62.5	62.5
Working Capital	261.39	255.76	210.63	211.86	204.71	315.1
Book Value Per Share	7.45	7.45	7.25	7.06	7.01	6.89
Tangible Book Value	445.1	443.04	431.77	422.52	418.79	411.42
Tangible Book Value Per Share	7.12	7.12	6.91	6.76	6.70	6.58
Buildings	-	201.18	200.12	187.2	75.35	0.88
Machinery	-	40	37.41	33.09	7.79	5.35
Construction In Progress	-	0.2	1.38	4.79	40.47	54.11

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.